

Na otázku, zda kombinace diosmin/hesperidinová frakce je účinným tandemem či zda je hesperidin jen neúčinnou příměsí, lze odpovědět jednoznačně. Každý z flavonoidů má svůj farmakodynamický účinek a pouze pro kombinaci obou složek existují doklady o účinku. Jak dokládá

též experimentální práce, kombinace jednotlivých složek flavonoidů má, minimálně na úrovni antiexudativního působení, synergistický účinek (19). Rozhodně tak není možno souhlasit s tvrzením, že jedinou účinnou látkou je diosmin a ostatní flavonoidy jsou jen neúčinnou příměsí.

LITERATURA

- Ligi D, Croce L, Mannello F. Chronic venous disorders: The dangerous, the good, and the diverse. *Int. J. Mol. Sci.* 2018; 19: 2544.
- Wittens C, et al. Management of Chronic Venous Disease. Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2015; 49: 678–737.
- Nicolaidis A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. *Int Angiol* 2018, June 37(3): 232–254.
- Karetová D. Chronická žilní onemocnění končetin ve světle mezinárodních doporučení publikovaných v roce 2018 (Guidelines for the management of chronic venous disorders of the lower limbs, *Int Angiol*, 2018), Postgraduální medicína 2019, ročník 21, č. 1: 52–57.
- Ding Z, Sun G, Zhu Z. Hesperidin attenuates influenza A virus (H1N1)-induced lung injury in rats through its anti-inflammatory effect. *Antivir Ther.* 2018 Apr. doi: 10.3851/IMP3235.
- Lee HJ, Im AR, Kim SM et al. The flavonoid hesperidin exerts anti-photoaging effect by downregulating matrix metalloproteinase (MMP)-9 expression via mitogen activated protein kinase (MAPK)-dependent signaling pathways. *BMC Complement Altern Med.* 2018 Jan 30;18(1):39. doi: 10.1186/s12906-017-2058-8.
- Tejada S, Pinya S, Martorell M et al. Potential anti-inflammatory effects of hesperidin from the genus Citrus. *Curr Med Chem.* 2017 Jul 18. doi: 10.2174/0929867324666170718104412
- Parhiz H, Roohbakhsh A, Soltani F, et al. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. *Phytother Res.* 2015 Mar;29(3): 323–331. doi: 10.1002/ptr.5256
- Milenkovic D, Deval C, Dubray C, et al. Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. *PLoS One.* 2011; 6(11): e26669.
- Salden BN, Troost FJ, de Groot E, et al. Randomized clinical trial on the efficacy of hesperidin 25 on validated cardiovascular biomarkers in healthy overweight individuals. *Am J Clin Nutr.* 2016 Dec;104(6): 1523–1533.
- Haidari F, Heybar H, Jalali MT, et al. Hesperidin supplementation modulates inflammatory responses following myocardial infarction. *J Am Coll Nutr.* 2015; 34(3): 205–211.
- Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. *J Clin Endocrinol Metab.* 2011; 96(5): E782–792.
- Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. *Am J Clin Nutr.* 2011; 93(1): 73–80.
- Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schonbein GW. Venous hypertension, inflammation and valve remodeling. *Eur. J. Vasc. Endovasc. Surg.* 2004; 28: 484–493.
- Das Gracias CDSM, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension. *Eur. J. Vasc. Endovasc. Surg.* 2018;55: 694–702.
- Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. *Int. Angiol.* 1988; 7: 39–43.
- Efficacy and Safety of Diosmin 600 mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs (EDEN), *ClinicalTrials.gov* Identifier: NCT01532882.
- Feldo M, Wójciak-Kosior M, Sowa I, et al. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. *Molecules.* 2019; 24(18): 3316.
- Paysant J, Sansilvestri-Morel P, Bouskela E, et al. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. *Int Angiol.* 2008; 27(1): 81–85.
- Amato C. Advantage of a micronized flavonoid fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin. *Angiology* 1994; 45: 531–536.
- Cospite M, Dominici A. Advantage of micronisation of Daflon 500 mg compared with a simple diosmine in the treatment of venous insufficiency. Double blind study. *Phlebologie* 1998; 51: 243–247.
- Henriet J-P. Insuffisance veineuse fonctionnelle: essai clinique comparatif d'une se- ule prise par jour de Diovenor® 600 mg (600 mg de diosmine d'hémisynthèse) versus 2 prises par jour d'un mélange de 500 mg de flavonoides (900 mg de diosmine). *Phlebologie* 1995; 48: 285–290.
- Clinical Non-inferiority Study Between Diosmin 600 mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency. *ClinicalTrials.gov* Identifier: NCT03471910.
- Nicolaidis A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. *Int Angiol.* 37(3): 181–254. doi: 10.23736/S0392-9590.18.03999-8.
- Jantet G. RELIEF study: first consolidated European data. Reflux assessment and quality of life improvement with micronized Flavonoids. *Angiology* 2000; 51: 31–37.
- Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavonoid Fraction (MPFF). *Phlebology* 2017; 32 (1_suppl): 3–19.
- Aziz Z, Huin WK, Badrul Hisham MD, Tang WL, Yaacob S. Efficacy and tolerability of micronized purified flavonoid fractions (MPFF) for haemorrhoids: A systematic review and meta-analysis. *Complement Ther Med* 2018; 39: 49–55.
- Kakkos SK, Nicolaidis AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. *Int Angiol* 2018; 37: 143–154.
- Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. *Eur J Vasc Endovasc Surg* 2005; 30: 198–208.
- Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. *Int Angiol* 2012; 31: 310–315.

Dlouhodobě usilujeme o společensky odpovědný přístup k našemu podnikání. Důkazem je titul:



Odpovědná firma roku 2019 Olomouckého kraje

SOLEN MEDICAL EDUCATION